Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RevvityRVTY +0.37%78 EV-to-OCF is 24.07 as of Aug. 08, 2026, which is 8% below its 10-year median of 26.11. GuruFocus rates RVTY with a GF Score™ of 78/100 and a GF Value™ of $117.91 (Fairly Valued). The stock has 11 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Revvity ranks worse than 79.34% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Revvity's Enterprise Value is $15,110 Mil.
Revvity's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $628 Mil. Therefore, Revvity's EV-to-OCF for today is 24.07.
The historical rank and industry rank for Revvity's EV-to-OCF or its related term are showing as below:
RVTY'
s EV-to-OCF Range Over the Past 10 Years
Min: 12.53 Med: 26.11 Max: 477.89
Current: 24.07
During the past 13 years, the highest EV-to-OCF of Revvity was 477.89. The lowest was 12.53. And the median was 26.11.
RVTY's EV-to-OCF is ranked worse than 79.34% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.26
vs RVTY: 24.07
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Revvity's share price for today is $114.66.
Revvity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.095.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Revvity EV-to-OCF Related Terms
Revvity EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Revvity's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Revvity's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Revvity's EV-to-OCF falls into.
Revvity's current Enterprise Value is $15,110 Mil.
Revvity's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $628 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (RVTY) has a EV-to-OCF of 24.07 as of Aug. 08, 2026. This is near median its historical median of 26.11. Over the past decade, Revvity's EV-to-OCF has ranged from 12.53 to 477.89. According to the industry distribution chart, Revvity ranks #169 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 79.3%.
Is Revvity's EV-to-OCF too high?
Revvity's current EV-to-OCF of 24.07 is near median its 10-year median of 26.11. Over the past 10 years, this metric has ranged from a low of 12.53 to a high of 477.89. The Medical Diagnostics & Research industry median EV-to-OCF is 6.26. Revvity's value of 24.07 is 284.5% above this industry median. Based on the distribution chart, Revvity ranks #169 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Revvity has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Revvity's EV-to-OCF compare to ICLR and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #169 out of 213 companies for EV-to-OCF. This places Revvity in the lower half of its industry. The industry median EV-to-OCF is 6.26. Revvity's value of 24.07 is 284.5% above this benchmark. Historically, Revvity's own EV-to-OCF has ranged from 12.53 to 477.89 over the past decade. While the company's 10-year median is 26.11 vs. the industry median of 6.26, Revvity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.26, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revvity's current EV-to-OCF of 24.07 is 284.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revvity's current EV-to-OCF is 24.07, which is near median its own 10-year median of 26.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (RVTY) is currently considered Fairly Valued. The stock's GF Value™ is $117.91, compared to a current price of $114.66 — trading 2.8% below its estimated fair value. The current EV-to-OCF is 24.07, which is near median its 10-year median of 26.11 and 284.5% above the Medical Diagnostics & Research industry median of 6.26. Revvity's overall GF Score™ is 78/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Revvity (RVTY), the current EV-to-OCF is 24.07 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (RVTY) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of $114.66 is trading 2.8% below its estimated GF Value™ of $117.91.
GuruFocus considers Revvity to be Fairly Valued.
Key valuation signals for RVTY:
EV-to-OCF: 24.07 (near median its 10-year median of 26.11)
GF Value™: $117.91 vs. price of $114.66 (2.8% below fair value)
Industry Position: 284.5% above the Medical Diagnostics & Research median (#169 of 213)
No single metric tells the full story. See the RVTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
78GF Score
Get the complete analysis for RVTY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVTY has been successfully added to your 
